|
* The United States and Arab allies bombed Syria
for the first time on Tuesday, killing dozens of Islamic State
fighters and members of a separate al Qaeda-linked group,
pursuing a campaign against militants into a war at the heart of
the Middle East.
* U.S.-listed shares of Shire <SHPG.O>, down 5.8 percent to
$241.35 and AstraZeneca <AZN.N>, off 4.6 percent to $71.25, lost
ground in premarket after the Obama administration took several
actions late Monday that will reduce the tax benefits available
to companies that have done inversion deals, while also making
new inversions more difficult to do and potentially less
rewarding.
* Shares of AbbVie <ABBV.N>, which has agreed to a deal to
acquire Shire, was down 4.6 percent to $56 before the opening
bell.
* Data expected on Tuesday includes the flash September reading
on manufacturing from financial data firm Markit at 9:45 a.m.
EDT. Expectations call for a reading in the main purchasing
managers' index of 58 versus the final 57.9 in August.
* Salix Pharmaceuticals <SLXP.O> was trading up 7.8 percent to
$172.30 in light premarket trade after a person familiar with
the matter said on Monday Allergan Inc <AGN.N> has revived
discussions to buy Salix.
* Norway's Yara <YAR.OL> and Chicago-based CF Industries <CF.N>
are in talks about a merger of equals that could create a $27
billion global fertilizer producer, rivaling Canada's Potash
Corp <POT.TO> in size in a fragmented and oversupplied market.
* S&P 500 e-minis <ESc1> were falling 6 points, or 0.3 percent,
with 151,091 contracts changing hands.
* Nasdaq 100 e-minis <NQc1> were down 14.25 points, or 0.35
percent, in volume of 23,930 contracts.
* Dow e-minis <1YMc1> were down 40 points, or 0.23 percent, with
21,482 contracts changing hands.
(Reporting by Chuck Mikolajczak)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
